161,555 Illumina, Inc. $ILMN Shares Purchased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 52.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 469,340 shares of the life sciences company’s stock after buying an additional 161,555 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Illumina were worth $128,449,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Fiduciary Financial Advisors bought a new stake in shares of Illumina in the second quarter worth $26,000. MCF Advisors LLC boosted its holdings in Illumina by 172.4% during the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 100 shares during the last quarter. Keating Financial Advisory Services Inc. acquired a new position in Illumina during the second quarter worth $32,000. Rakuten Securities Inc. acquired a new position in Illumina during the second quarter worth $33,000. Finally, Elevation Wealth Partners LLC grew its position in Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Illumina

In other news, Director Keith Meister sold 457,858 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the transaction, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. The trade was a 16.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have sold 2,061,850 shares of company stock valued at $436,479,102. Company insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Guggenheim lifted their price target on shares of Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Evercore restated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Sunday, October 11th. Argus raised their price objective on Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. Finally, UBS Group raised Illumina from a “neutral” rating to a “buy” rating and lifted their target price for the company from $135.00 to $260.00 in a research report on Wednesday, September 9th. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Illumina currently has an average rating of “Hold” and a consensus target price of $231.88.

Illumina Trading Up 5.6%

NASDAQ ILMN opened at $282.86 on Thursday. The company has a market cap of $42.71 billion, a PE ratio of 52.77, a PEG ratio of 3.79 and a beta of 1.41. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12 month low of $94.00 and a 12 month high of $309.35. The stock has a 50 day moving average of $239.24 and a 200-day moving average of $189.54.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.